MANGOCEUTICALS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
Mangoceuticals, Inc.
Statements of Operations
| For The Year | For The Year | |
|---|---|---|
| Ended | Ended | |
| December 31, 2023 | December 31, 2022 | |
| Revenues | ||
| Revenues | $731,493 | $8,939 |
| Cost of revenues | 154,900 | 4,089 |
| Cost of revenues - related party | 145,092 | - |
| Gross profit | 431,501 | 4,850 |
| Operating expenses | ||
| General and administrative expenses | 3,319,417 | 1,643,572 |
| Salary and benefits | 977,890 | - |
| Advertising and marketing | 2,097,505 | 352,860 |
| Investor relations | 1,100,465 | - |
| Stock based compensation | 2,155,114 | - |
| Total operating expenses | 9,650,391 | 1,996,432 |
| Loss from operations | (9,218,890) | (1,991,582) |
| Other (income) expense | ||
| Other income | (6,473) | - |
| Imputed interest - related party | - | 6,473 |
| Total other (income) expense | (6,473) | 6,473 |
| Loss before income taxes | (9,212,417) | (1,998,055) |
| Income taxes | - | - |
| Net loss | $(9,212,417) | $(1,998,055) |
| Basic and diluted loss per share | ||
| Basic and diluted loss per share | $(0.57) | $(0.19) |
| Weighted average number of shares outstanding | ||
| Basic and diluted | 16,113,029 | 10,798,083 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.